Clinical Trial

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-13; most recent amendment 2025-12-30.
Status change: Not Yet Recruiting → Recruiting 2025-12-30
Trial Details
NCT Number NCT06883526
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Lymphoma
Enrollment 60 participants
Start Date 2025-05-16
Primary Completion 2027-04 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-05